Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Mizuho Analyst Says

Insmed (NASDAQ:INSM) had its price objective hoisted by Mizuho from $204.00 to $206.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s target price suggests a potential upside of 40.71% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. TD Cowen set a $241.00 price objective on shares of Insmed in a research report on Thursday, December 18th. Wells Fargo & Company lowered their price target on Insmed from $208.00 to $175.00 and set an “overweight” rating for the company in a report on Monday. Leerink Partners raised their price objective on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research report on Tuesday. Wolfe Research set a $167.00 target price on Insmed and gave the stock an “outperform” rating in a research report on Thursday, December 18th. Finally, UBS Group lowered their target price on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of “Buy” and an average price target of $209.48.

Insmed Trading Up 5.2%

Shares of NASDAQ INSM traded up $7.26 during midday trading on Wednesday, hitting $146.40. The stock had a trading volume of 412,543 shares, compared to its average volume of 2,456,071. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a market capitalization of $31.56 billion, a price-to-earnings ratio of -22.78 and a beta of 1.13. The company has a fifty day moving average price of $150.99 and a 200 day moving average price of $166.23.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same period last year, the company posted ($1.32) EPS. The firm’s revenue for the quarter was up 152.6% compared to the same quarter last year. On average, analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 791 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total transaction of $123,530.47. Following the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $16,680,517.70. This trade represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 748 shares of Insmed stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $116,942.32. Following the completion of the transaction, the chief financial officer owned 79,758 shares of the company’s stock, valued at $12,469,365.72. This trade represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 189,651 shares of company stock valued at $31,533,654. Insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently bought and sold shares of the company. Norges Bank bought a new stake in Insmed in the fourth quarter valued at $506,625,000. Vanguard Group Inc. grew its position in shares of Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after acquiring an additional 2,291,328 shares during the last quarter. RTW Investments LP increased its holdings in shares of Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after acquiring an additional 1,758,321 shares during the period. Artisan Partners Limited Partnership lifted its position in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares during the last quarter. Finally, Orbis Allan Gray Ltd acquired a new position in Insmed during the 2nd quarter valued at about $153,389,000.

More Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Late‑stage ENCORE Phase 3b results show ARIKAYCE met key goals versus standard therapy, supporting a potential label expansion into first‑line MAC lung disease and a bigger commercial opportunity for the drug. This is the primary catalyst driving investor optimism. Read More.
• Positive Sentiment: Wall Street reacted with multiple target upgrades and bullish coverage — Bank of America, Leerink Partners and Stifel raised targets or ratings (BofA to ~$213, Leerink to $215, Stifel to $208), implying roughly 50%+ upside from recent levels and signaling increased confidence in ARIKAYCE’s commercial upside. Read More.
• Positive Sentiment: Analyst commentary and independent writeups (Seeking Alpha, Zacks, MarketWatch/press coverage) are framing the news as a material expansion opportunity and reiterating buy/strong‑buy views, reinforcing investor momentum. Read More.
• Neutral Sentiment: Short‑interest reports in the feeds show large percentage changes but the underlying numbers appear inconsistent/invalid (zeros/NaN). At face value the data aren’t showing a meaningful days‑to‑cover signal; treat the short‑interest items as unreliable until updated data are posted.
• Negative Sentiment: Wells Fargo trimmed its price target from $208 to $175 (still an overweight/positive stance), a more conservative read that could cap upside or introduce some intraday volatility as investors weigh varied analyst views. Read More.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.